Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)
Giacomo Ponta, Valentina Morena, Martina Strano, Chiara Molteni, Silvia Pontiggia, Erica Michela Cavalli, Anna Grancini, Carola Mauri, Antonella Castagna, Andrea Galanti, Stefania Piconi
Abstract
ABSTRACT Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia. Few data are available about the long-term use of rezafungin and its use for deep infections like endocarditis and osteomyelitis. We describe our experience with its prolonged use in two azole-resistant Candida infections: a case of sacral osteomyelitis and a prosthetic valve endocarditis also involving a thoracic endovascular aneurysm repair.
Topics & Concepts
EchinocandinOsteomyelitisMedicineEndocarditisSurgeryAzoleAntifungalFluconazoleDermatologyAntifungal resistance and susceptibilityFungal Infections and StudiesNail Diseases and Treatments